Mark Dittmar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Dittmar has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Sara Cherry
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
5 shared publications - David C. Schultz
University of Pennsylvania Department of Biochemistry and Biophysics Philadelphia , PA 19104
3 shared publications - Kanupriya Whig
Institute for Immunology, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104, USA; High-Throughput Screening Core, University of Pennsylvania, Philadelphia, PA 19104, USA
3 shared publications Brinda Kamalia
Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, USA
2 shared publications- Brinda Kamalia
Department of Biochemistry and Biophysics, University of Pennsylvania , 3620 Hamilton Walk Philadelphia, PA 19104 , USA
2 shared publications - Holly Ramage
Department of Microbiology and Immunology, Thomas Jefferson University
2 shared publications
Latest Publications
- Open Access
- 3 August 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (9) , pgad256
Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus
Rubella is a highly contagious viral infection that usually causes a mild disease in children and adults. However, infection during pregnancy can result in a fetal or newborn death or congenital rubella syndrome (CRS), a constellation of permanent birth defects including cataracts, heart defects, and sensorineural deafness. The live-attenuated rubella vaccine has been highly effective, with the Americas declared free of endemic rubella transmission in 2015. However, rubella remains a significant problem worldwide and the leading cause of vaccine-preventable birth defects globally. Thus, elimination of rubella and CRS is a goal of the World Health Organization. No specific therapeutics are approved for the rubella virus. Therefore, we set out to identify whether existing small molecules may be repurposed for use against rubella virus infection. Thus, we performed a high-throughput screen for small molecules active against rubella virus in human respiratory cells and identified two nucleoside analogs, NM107 and AT-527, with potent antiviral activity. Furthermore, we found that combining these nucleoside analogs with inhibitors of host nucleoside biosynthesis had synergistic antiviral activity. These studies open the door to new potential approaches to treat rubella infections.
- 3 August 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (9) , pgad256
Open AccessNucleoside analogs NM107 and AT-527 are antiviral against rubella virus
Rubella is a highly contagious viral infection that usually causes a mild disease in children and adults. However, infection during pregnancy can result in a fetal or newborn death or congenital rubella syndrome (CRS), a constellation of permanent birth defects including cataracts, heart defects, and sensorineural deafness. The live-attenuated rubella vaccine has been highly effective, with the Americas declared free of endemic rubella transmission in 2015. However, rubella remains a significant problem worldwide and the leading cause of vaccine-preventable birth defects globally. Thus, elimination of rubella and CRS is a goal of the World Health Organization. No specific therapeutics are approved for the rubella virus. Therefore, we set out to identify whether existing small molecules may be repurposed for use against rubella virus infection. Thus, we performed a high-throughput screen for small molecules active against rubella virus in human respiratory cells and identified two nucleoside analogs, NM107 and AT-527, with potent antiviral activity. Furthermore, we found that combining these nucleoside analogs with inhibitors of host nucleoside biosynthesis had synergistic antiviral activity. These studies open the door to new potential approaches to treat rubella infections.
- 26 September 2022
- Published by Elsevier in Molecular Cell
- Vol. 82 (19) , 3729-3744.e10
The lncRNA ALPHA specifically targets chikungunya virus to control infection
- 26 September 2022
- Published by Elsevier in Molecular Cell
- Vol. 82 (19) , 3729-3744.e10
The lncRNA ALPHA specifically targets chikungunya virus to control infection
- Top Cited Papers
- 7 February 2022
- Published by Springer Nature in Nature
- Vol. 604 (7904) , 134-140
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
The SARS-CoV-2 virus has infected more than 261 million people and has led to more than 5 million deaths in the past year and a half1 (https://www.who.org/). Individuals with SARS-CoV-2 infection typically develop mild-to-severe flu-like symptoms, whereas infection of a subset of individuals leads to severe-to-fatal clinical outcomes2. Although vaccines have been rapidly developed to combat SARS-CoV-2, there has been a dearth of antiviral therapeutics. There is an urgent need for therapeutics, which has been amplified by the emerging threats of variants that may evade vaccines. Large-scale efforts are underway to identify antiviral drugs. Here we screened approximately 18,000 drugs for antiviral activity using live virus infection in human respiratory cells and validated 122 drugs with antiviral activity and selectivity against SARS-CoV-2. Among these candidates are 16 nucleoside analogues, the largest category of clinically used antivirals. This included the antivirals remdesivir and molnupiravir, which have been approved for use in COVID-19. RNA viruses rely on a high supply of nucleoside triphosphates from the host to efficiently replicate, and we identified a panel of host nucleoside biosynthesis inhibitors as antiviral. Moreover, we found that combining pyrimidine biosynthesis inhibitors with antiviral nucleoside analogues synergistically inhibits SARS-CoV-2 infection in vitro and in vivo against emerging strains of SARS-CoV-2, suggesting a clinical path forward.
- 7 February 2022
- Published by Springer Nature in Nature
- Vol. 604 (7904) , 134-140
Top Cited PapersPyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
The SARS-CoV-2 virus has infected more than 261 million people and has led to more than 5 million deaths in the past year and a half1 (https://www.who.org/). Individuals with SARS-CoV-2 infection typically develop mild-to-severe flu-like symptoms, whereas infection of a subset of individuals leads to severe-to-fatal clinical outcomes2. Although vaccines have been rapidly developed to combat SARS-CoV-2, there has been a dearth of antiviral therapeutics. There is an urgent need for therapeutics, which has been amplified by the emerging threats of variants that may evade vaccines. Large-scale efforts are underway to identify antiviral drugs. Here we screened approximately 18,000 drugs for antiviral activity using live virus infection in human respiratory cells and validated 122 drugs with antiviral activity and selectivity against SARS-CoV-2. Among these candidates are 16 nucleoside analogues, the largest category of clinically used antivirals. This included the antivirals remdesivir and molnupiravir, which have been approved for use in COVID-19. RNA viruses rely on a high supply of nucleoside triphosphates from the host to efficiently replicate, and we identified a panel of host nucleoside biosynthesis inhibitors as antiviral. Moreover, we found that combining pyrimidine biosynthesis inhibitors with antiviral nucleoside analogues synergistically inhibits SARS-CoV-2 infection in vitro and in vivo against emerging strains of SARS-CoV-2, suggesting a clinical path forward.
- Open Access
- 24 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0253089
SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating global pandemic, infecting over 43 million people and claiming over 1 million lives, with these numbers increasing daily. Therefore, there is urgent need to understand the molecular mechanisms governing SARS-CoV-2 pathogenesis, immune evasion, and disease progression. Here, we show that SARS-CoV-2 can block IRF3 and NF-κB activation early during virus infection. We also identify that the SARS-CoV-2 viral proteins NSP1 and NSP13 can block interferon activation via distinct mechanisms. NSP1 antagonizes interferon signaling by suppressing host mRNA translation, while NSP13 downregulates interferon and NF-κB promoter signaling by limiting TBK1 and IRF3 activation, as phospho-TBK1 and phospho-IRF3 protein levels are reduced with increasing levels of NSP13 protein expression. NSP13 can also reduce NF-κB activation by both limiting NF-κB phosphorylation and nuclear translocation. Last, we also show that NSP13 binds to TBK1 and downregulates IFIT1 protein expression. Collectively, these data illustrate that SARS-CoV-2 bypasses multiple innate immune activation pathways through distinct mechanisms.
- 24 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0253089
Open AccessSARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating global pandemic, infecting over 43 million people and claiming over 1 million lives, with these numbers increasing daily. Therefore, there is urgent need to understand the molecular mechanisms governing SARS-CoV-2 pathogenesis, immune evasion, and disease progression. Here, we show that SARS-CoV-2 can block IRF3 and NF-κB activation early during virus infection. We also identify that the SARS-CoV-2 viral proteins NSP1 and NSP13 can block interferon activation via distinct mechanisms. NSP1 antagonizes interferon signaling by suppressing host mRNA translation, while NSP13 downregulates interferon and NF-κB promoter signaling by limiting TBK1 and IRF3 activation, as phospho-TBK1 and phospho-IRF3 protein levels are reduced with increasing levels of NSP13 protein expression. NSP13 can also reduce NF-κB activation by both limiting NF-κB phosphorylation and nuclear translocation. Last, we also show that NSP13 binds to TBK1 and downregulates IFIT1 protein expression. Collectively, these data illustrate that SARS-CoV-2 bypasses multiple innate immune activation pathways through distinct mechanisms.
- Open Access
- 28 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (59)
Pharmacological activation of STING blocks SARS-CoV-2 infection
Pharmacological activation of STING blocks SARS-CoV-2 infection including variants of concern in vitro and in vivo.
- 28 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (59)
Open AccessPharmacological activation of STING blocks SARS-CoV-2 infection
Pharmacological activation of STING blocks SARS-CoV-2 infection including variants of concern in vitro and in vivo.
- Open Access
- 1 April 2021
- Published by Elsevier in Cell Reports
- Vol. 35 (1) , 108959
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
- 1 April 2021
- Published by Elsevier in Cell Reports
- Vol. 35 (1) , 108959
Open AccessDrug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2